Case report

*Mycobacterium xenopi* pulmonary infection in an HIV infected patient under highly active antiretroviral treatment

C Bachmeyer, L Blum, S Stelianides, B Benchaa, N Gruat, O Danne

Abstract

Highly active antiretroviral therapy (HAART) is responsible for a striking reduction in AIDS related morbidity and mortality by partly restoring immune function. However, HAART can also precipitate the development of clinically apparent opportunistic infections in patients with latent infections. We report a case of an HIV infected patient who developed granulomatous nodular and cavitatory lesions of the lungs due to *Mycobacterium xenopi* as a manifestation of the immune restoration syndrome. (*Thorax* 2001;56:978–979)

Keywords: *Mycobacterium xenopi*; HIV; HAART; immune restoration syndrome

Highly active antiretroviral therapy (HAART) is responsible for a striking reduction in AIDS related morbidity and mortality by partly restoring immune function. Improvement and resolution of opportunistic infections has been most commonly observed. Unfortunately, HAART can also precipitate the development of clinically apparent opportunistic infections in patients with latent infections within the first weeks of treatment.1–4 We report a *Mycobacterium xenopi* pulmonary infection presenting with granulomatous nodular and cavitatory lesions as a complication of the immune restoration syndrome.

Case report

In July 1999 treatment with zidovudine, lamivudine, and fortovase associated with cotrimoxazole was started in a 35 year old woman with HIV-1 infection in whom the CD4+ lymphocyte count was 48/mm3 and the viral load was 150 229 HIV RNA copies/ml. One month later her temperature was 38°C and isolated serum positivity for cryptococcal antigen was discovered which was controlled with fluconazole. In September 1999 she presented with cough and a fever of 38.5°C. A chest radiograph and CT scan demonstrated bilateral nodules of the lungs and cavitations in the left lower lobe, but no lymph nodes (fig 1). At this time the CD4+ lymphocyte count was 225/mm3 and the viral load was 114 HIV RNA copies/ml. The tuberculin skin reaction was negative and liver function tests were unremarkable. Serological tests for *Coxiella burnetii*, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Legionella* were either negative or did not suggest recent infection. Direct microscopic examination of sputum was negative. Bronchoscopic examination, direct search for pathogens on bronchoalveolar lavage specimens and transbronchial biopsy specimen were normal or negative. A CT guided percutaneous biopsy of a nodule was therefore performed. Histological examination showed an epithelioid cell granuloma. As mycobacterial infection was suspected, efavirenz was substituted for fortovase, and antimycobacterial treatment combining isoniazid, rifampicin, and ethambutol was commenced. Cultures from one sputum out of three grew *Mycobacterium xenopi* which was sensitive to all of the drugs, whereas cultures from the transbronchial biopsy specimen were negative. A dramatic improvement in clinical symptoms and in radiographic features was observed within 2 months.

Discussion

The development of opportunistic infections during the first 2 months of HAART has

Figure 1  **CT scan of the chest showing multiple nodular lesions and cavitation of the left lower lobe.**
M. xenopi pulmonary infection in an HIV infected patient receiving HAART

M. xenopi pulmonary infection in an HIV infected patient receiving HAART. Indeed, clinically silent infections may become apparent as a result of restoration of specific immune activity against microbial pathogens. This results from intensified inflammatory responses caused by the sudden increase in lymphocytes specifically reacting, for example, against mycobacterial antigens in mycobacterial infections.

We present a case of M. xenopi pulmonary infection as a complication of the immune restoration syndrome. To the best of our knowledge only one similar case has been reported. Mycobacterium xenopi is a scotochromogenic, acid fast, slow growing, non-tuberculous bacillus, growing optimally at 42°C. It is usually considered as a commensal, saprophyte, or environmental contaminant. Its pathogenicity is relatively low and infection requires impairment of host immunity. Infection usually occurs in the lungs in patients with chronic obstructive pulmonary disease, chronic alcoholism, diabetes mellitus, and malignancies. Radiographically it presents with multinodular densities and cavitations. Granuloma formation is typical of such an infection when available. No treatment guide- lines exist for pulmonary infection when available. No treatment guidelines exist for pulmonary M. xenopi infection, but a combination of three or four drugs which might include streptomycin, ethionamide, and ethambutol or rifampicin continued for 18–24 months seems reasonable. In vitro drug susceptibility and response to chemotherapy are unpredictable. In a few cases surgical resection resulted in cure when antibiotics were ineffective. Of note, diagnosis of uncommon—that is, other than M. avium complex and M. kansasii—non-tuberculous mycobacterial disease in HIV negative patients relies on the criteria of the American Thoracic Society: (a) either repeated isolation from a non-sterile site or a single isolation of M. xenopi from a normally sterile localisation and (b) either the presence of one or more symptoms indicative of pulmonary disease or an abnormal chest radiograph, in the absence of other pathogens or illnesses.

Mycobacterium xenopi has been reported as being responsible for pulmonary and extra-pulmonary infections in HIV infected patients. Fever and cough are common symptoms in these patients, and fever is significantly more frequent in patients with AIDS than in non-AIDS patients. Radiographic find- ings include interstitial and mixed disease, rarely a reticulonodular pattern and cavitary disease, but adenopathy is unusual. Most patients have advanced HIV infection with a CD4 cell count of <100/mm³. Differential diagnosis includes Pneumocystis carinii pneumonia, other mycobacterial infections, and sarcoidosis which has also recently been described as the result of the immune restoration syndrome.

In our patient the diagnosis of M. xenopi pulmonary infection was likely on clinical, radiological, and histological findings, despite only one specimen of sputum being positive for the organism. Indeed, the diagnostic criteria of the American Thoracic Society were not fulfilled. However, we consider that this result should not be attributed to environmental contamination.
Mycobacterium xenopi pulmonary infection in an HIV infected patient under highly active antiretroviral treatment

C Bachmeyer, L Blum, S Stelianides, B Benchaa, N Gruat and O Danne

Thorax 2001 56: 978-979
doi: 10.1136/thorax.56.12.978

Updated information and services can be found at:
http://thorax.bmj.com/content/56/12/978

These include:

References
This article cites 9 articles, 0 of which you can access for free at:
http://thorax.bmj.com/content/56/12/978#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: infectious diseases (968)
- HIV/AIDS (194)
- Epidemiologic studies (1829)
- TB and other respiratory infections (1273)
- Lung infection (97)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/